See more : AnalytixInsight Inc. (ATIXF) Income Statement Analysis – Financial Results
Complete financial analysis of NeoGenomics, Inc. (NEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeoGenomics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Henan Jinma Energy Company Limited (6885.HK) Income Statement Analysis – Financial Results
- Ameresco, Inc. (AMRC) Income Statement Analysis – Financial Results
- Detection Technology Oyj (DETEC.HE) Income Statement Analysis – Financial Results
- Energy Development Company Limited (ENERGYDEV.BO) Income Statement Analysis – Financial Results
- Utron Ltd (UTRN.TA) Income Statement Analysis – Financial Results
NeoGenomics, Inc. (NEO)
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 258.61M | 244.08M | 99.80M | 87.07M | 66.47M | 59.87M | 43.48M | 34.37M | 29.47M | 20.02M | 11.50M | 6.48M | 1.89M | 558.07K | 369.97K | 93.49K | 1.00K | 252.40K |
| Cost of Revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M | 149.48M | 138.30M | 133.70M | 56.05M | 46.36M | 34.73M | 33.03M | 24.06M | 18.59M | 14.25M | 9.35M | 5.52M | 2.76M | 1.19M | 576.87K | 481.59K | 189.96K | 0.00 | 74.29K |
| Gross Profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M | 127.27M | 120.32M | 110.38M | 43.76M | 40.71M | 31.74M | 26.84M | 19.43M | 15.78M | 15.21M | 10.66M | 5.98M | 3.72M | 696.92K | -18.79K | -111.62K | -96.47K | 1.00K | 178.11K |
| Gross Profit Ratio | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 46.52% | 45.22% | 43.84% | 46.76% | 47.75% | 44.83% | 44.68% | 45.92% | 51.63% | 53.27% | 52.00% | 57.39% | 36.97% | -3.37% | -30.17% | -103.18% | 100.00% | 70.57% |
| Research & Development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M | 4.20M | 2.69M | 2.44M | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.41K | 0.00 | 0.00 |
| General & Administrative | 243.10M | 243.36M | 221.35M | 143.79M | 127.99M | 84.82M | 88.76M | 75.78M | 33.63M | 23.81M | 17.40M | 15.84M | 12.87M | 11.27M | 10.06M | 0.00 | 0.00 | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 0.00 | 0.00 |
| Selling & Marketing | 70.84M | 67.32M | 62.59M | 47.86M | 47.35M | 29.40M | 24.54M | 23.91M | 11.56M | 12.00M | 8.73M | 7.50M | 6.96M | 7.48M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 313.04M | 310.68M | 283.94M | 191.66M | 175.34M | 114.22M | 113.30M | 99.69M | 45.19M | 35.81M | 26.12M | 23.34M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 8.08M | 1.12M |
| Other Expenses | 11.99M | -213.00K | -499.00K | 11.86M | -4.63M | 14.00K | -1.32M | 3.46M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K |
| Operating Expenses | 352.34M | 341.00M | 305.81M | 199.89M | 183.83M | 117.23M | 116.93M | 104.34M | 49.39M | 38.50M | 28.56M | 25.63M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 487.21K | 8.08M | 1.15M |
| Cost & Expenses | 699.38M | 662.84M | 603.08M | 458.44M | 395.82M | 266.70M | 255.23M | 238.05M | 105.44M | 84.85M | 63.29M | 58.66M | 43.89M | 37.33M | 31.20M | 20.90M | 14.65M | 6.34M | 2.69M | 1.29M | 864.30K | 677.16K | 8.08M | 1.22M |
| Interest Income | 16.90M | 6.08M | 3.14M | 3.06M | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.91M | 1.51M | 5.08M | 7.02M | 3.71M | 6.23M | 5.54M | 10.00M | 854.00K | 929.00K | 989.00K | 1.15M | 768.00K | 710.00K | 532.39K | 308.52K | 0.00 | 325.63K | 196.80K | 0.00 | 41.43K | 207.31K | 0.00 | 0.00 |
| Depreciation & Amortization | 72.58M | 79.21M | 62.07M | 41.89M | 35.91M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.40K |
| EBITDA | -17.61M | -78.63M | 52.08M | 34.85M | 43.26M | 31.79M | 26.55M | 29.25M | 3.51M | 7.86M | 7.59M | 5.03M | 1.68M | -812.00K | -526.31K | -143.43K | -2.63M | 446.58K | -619.30K | -625.30K | -446.30K | -583.67K | -7.83M | -944.53K |
| EBITDA Ratio | -2.98% | -16.46% | 8.95% | 7.56% | 9.45% | 11.49% | 9.53% | 11.98% | 3.51% | 2.55% | 4.78% | 8.40% | 3.85% | -4.52% | -1.90% | -0.77% | -23.11% | 6.03% | -32.85% | -112.05% | -120.63% | -624.31% | -783,229.50% | -374.47% |
| Operating Income | -107.74M | -153.11M | -9.99M | -2.13M | 8.38M | 10.04M | 3.38M | 2.57M | -5.64M | 2.22M | 3.17M | 1.21M | -409.00K | -2.96M | -1.73M | -883.99K | -3.14M | 139.99K | -800.36K | -729.56K | -494.33K | -583.67K | -8.08M | -970.93K |
| Operating Income Ratio | -18.21% | -30.04% | -2.06% | -0.48% | 2.05% | 3.63% | 1.31% | 1.05% | -5.65% | 2.55% | 4.78% | 2.02% | -0.94% | -8.62% | -5.86% | -4.42% | -27.30% | 2.16% | -42.45% | -130.73% | -133.61% | -624.31% | -807,796.60% | -384.67% |
| Total Other Income/Expenses | 10.64M | -1.72M | 103.68M | -64.00K | -9.36M | -6.22M | -5.55M | -10.00M | 1.15M | -929.00K | -989.00K | -1.15M | -768.00K | -340.00K | -515.30K | -498.60K | -239.20K | -139.99K | -196.80K | -89.42K | 0.00 | 0.00 | 0.00 | 646.00 |
| Income Before Tax | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M | 3.82M | -3.48M | -7.42M | -4.49M | 1.29M | 2.19M | 65.00K | -2.70K | -2.59M | -1.71M | -1.07M | -3.12M | 139.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -970.28K |
| Income Before Tax Ratio | -16.41% | -31.26% | -3.11% | -3.16% | 0.89% | 1.38% | -1.35% | -3.04% | -4.50% | 1.48% | 3.29% | 0.11% | -0.01% | -7.54% | -5.80% | -5.37% | -27.09% | 2.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -384.42% |
| Income Tax Expense | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M | 1.18M | -2.64M | -1.70M | -1.95M | 157.00K | 152.00K | 1.15M | 768.00K | -740.00K | -34.18K | 180.15K | 214.94K | -111.94K | 196.80K | 89.42K | 41.43K | 214.16K | 0.00 | -1.29K |
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846.00K | -5.72M | -2.54M | 1.13M | 2.03M | 65.00K | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Net Income Ratio | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.33% | -2.34% | -2.54% | 1.30% | 3.06% | 0.11% | -2.71% | -9.61% | -7.61% | -6.91% | -29.38% | -2.00% | -52.89% | -146.75% | -144.81% | -631.64% | -807,796.60% | -384.42% |
| EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| EPS Diluted | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| Weighted Avg Shares Out | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M | 91.57M | 78.16M | 77.04M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
| Weighted Avg Shares Out (Dil) | 125.50M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and...
NEO Battery Materials Confirms Stable and Unaffected Operations Amid South Korea's Declaration of Emergency Martial Law
TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, wishes to...
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
TORONTO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, announces that...
NEO Battery Materials to Develop High-Specification Silicon Anodes with OCSiAl Single Wall Carbon Nanotubes
TORONTO, Nov. 28, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce the signing of a Memorandum...
NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments & Pathway to Commercialization
TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased...
NEO Battery Materials Appoints Prominent South Korean Attorney, Mr. Seok Hyung Lee, as New Director and Announces Battery Board Transition Initiative
TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased...
NEO Battery Materials Awarded as Consortium Partner in $20M Recycled Silicon Battery Project by South Korean Government
TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “C o mpan y”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased...
Airbus says A330NEO jet China certification progressing smoothly
The head of Airbus China said on Tuesday that the certification for its A330NEO plane in China was going smoothly and that the first delivery in the country could come in 2025.
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.
NEO Battery Materials and Linde Korea Sign MOU to Collaborate on Commercialization of Silicon Anode Technology
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd.(T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is highly pleased to announce the signing of a Memorandum...
Source: https://incomestatements.info
Category: Stock Reports